Results of Meeting
Released
Released
Announcement PDF
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
ASX Announcement
27 November 2025
ReNerve Limited 2025 Annual General Meeting Results
ReNerve Limited (ASX, "ReNerve" or "the Company"), advises that the Annual General Meeting of Shareholders
was held today at 10.00am (AEDT).
In accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 (Cth), the details of the
Resolutions and the Proxies received in respect of each Resolution are set out in the attached summary. All
Resolutions were passed.
- ENDS -
This announcement has been approved for release by the Company’s Board of Directors.
For further information and enquiries, please contact:
Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au
Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au
About ReNerve Limited (ASX:RNV)
ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical
technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device
company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral
nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients
worldwide.
Proven Clinical Success
ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference
in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable
results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores
dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant
improvement that's changing lives.
2 | P a g e
Comprehensive Product Portfolio
ReNerve is advancing a complete suite of nerve repair solutions:
• NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of
surgery.
• Deep Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive and
cosmetic surgical cases.
• Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds.
• NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO
technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
• NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for
treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to
undergo additional sural nerve harvesting.
• NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve
repairs.
Market Leadership and Growth
With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue
growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution
for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at
US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1
Vision and Values
We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for
nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's
natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve
surgery.
1
Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)
Disclosure of Proxy Votes
ReNerve Limited
Annual General Meetings
Thursday, 27 November 2025
In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814
Proxy Votes
Poll Results (if
applicable)
Results
Resolution
Decided by
Show of
Hands (S) or
Poll (P)
Total Number of
Proxy Votes
exercisable by
proxies validly
appointed
FOR AGAINST ABSTAIN
PROXY'S
DISCRETION
FOR AGAINST ABSTAIN OUTCOME
1 ADOPTION OF REMUNERATION REPORT P 39,307,896
38,206,971
97.20%
219,706
0.56%
50,000
881,219
2.24%
39,094,078
99.44%
219,706
0.56%
50,000 -
2 RE-ELECTION OF NON-EXECUTIVE DIRECTOR – MR
STEPHEN COOPER
P 66,560,334
39,450,987
59.27%
27,053,128
40.64%
0
56,219
0.08%
50,156,528
64.96%
27,053,128
35.04%
0 Carried
3 APPROVAL TO ISSUE OPTIONS TO DR JULIAN
CHICK
P 40,980,146
38,618,221
94.24%
375,706
0.92%
127,500
1,986,219
4.85%
51,253,762
99.27%
375,706
0.73%
127,500 Carried
4 APPROVAL TO ISSUE OPTIONS TO DR DAVID
RHODES
P 40,980,146
38,618,221
94.24%
375,706
0.92%
127,500
1,986,219
4.85%
51,253,762
99.27%
375,706
0.73%
127,500 Carried
5 RATIFICATION OF PRIOR SHARES ISSUED P 66,432,834
64,161,909
96.58%
284,706
0.43%
127,500
1,986,219
2.99%
76,797,450
99.63%
284,706
0.37%
127,500 Carried
6 RATIFICATION OF PRIOR SHARES ISSUED TO
SCIENTIFIC ADVISORY BOARD MEMBER (DR BRYAN
LOEFFLER)
P 66,432,834
64,070,909
96.44%
325,706
0.49%
127,500
2,036,219
3.07%
76,756,450
99.58%
325,706
0.42%
127,500 Carried
7 RATIFICATION OF PRIOR SHARES ISSUED TO
SCIENTIFIC ADVISORY BOARD MEMBER (DR MIHIR
DESAI)
P 66,510,334
64,148,409
96.45%
375,706
0.56%
50,000
1,986,219
2.99%
76,783,950
99.51%
375,706
0.49%
50,000 Carried
8 RATIFICATION OF PRIOR SHARES ISSUED TO
SCIENTIFIC ADVISORY BOARD MEMBER (MR SEAN
MCCARTHY)
P 66,510,334
64,148,409
96.45%
375,706
0.56%
50,000
1,986,219
2.99%
76,783,950
99.51%
375,706
0.49%
50,000 Carried
Proxy Votes
Poll Results (if
applicable)
Results
Resolution
Decided by
Show of
Hands (S) or
Poll (P)
Total Number of
Proxy Votes
exercisable by
proxies validly
appointed
FOR AGAINST ABSTAIN
PROXY'S
DISCRETION
FOR AGAINST ABSTAIN OUTCOME
9 RATIFICATION OF PRIOR SHARES ISSUED TO
SCIENTIFIC ADVISORY BOARD MEMBER
(AUSTRALIAN INSTITUTE OF REGENERATIVE
SURGERY PTY LTD)
P 66,510,334
64,148,409
96.45%
375,706
0.56%
50,000
1,986,219
2.99%
76,783,950
99.51%
375,706
0.49%
50,000 Carried
10 RATIFICATION OF PRIOR SHARES ISSUED P 66,510,334
64,148,409
96.45%
375,706
0.56%
50,000
1,986,219
2.99%
76,783,950
99.51%
375,706
0.49%
50,000 Carried
11 APPROVAL OF THE PERFORMANCE RIGHTS AND
OPTION PLAN
P 41,057,646
38,655,721
94.15%
415,706
1.01%
50,000
1,986,219
4.84%
51,291,262
99.20%
415,706
0.80%
50,000 Carried
12 APPROVAL OF ADDITIONAL 10% PLACEMENT
CAPACITY
P 66,510,334
64,163,409
96.47%
360,706
0.54%
50,000
1,986,219
2.99%
76,798,950
99.53%
360,706
0.47%
50,000 Carried
Share your feedback
Discover